DOXOMA-L 20MG INJ VIAL

About

DOXOMA-L 20MG INJ VIAL is a liposomal formulation of doxorubicin, an anthracycline topoisomerase inhibitor widely used in cancer chemotherapy. This specialized formulation encapsulates doxorubicin within lipid vesicles, which allows for a prolonged circulation time in the bloodstream and preferential accumulation within tumor tissues through the enhanced permeability and retention (EPR) effect. This mechanism helps to deliver a higher concentration of the drug directly to cancer cells while potentially minimizing exposure to healthy tissues, thereby reducing common systemic toxicities such as cardiotoxicity and myelosuppression often associated with conventional doxorubicin. It exerts its cytotoxic effects by intercalating into DNA, inhibiting topoisomerase II, and generating free radicals, leading to DNA damage and apoptosis in rapidly dividing cancer cells, offering a more favorable safety profile.

Uses

• Treatment of Kaposi's sarcoma.
• Management of ovarian cancer.
• Therapy for multiple myeloma.
• Treatment of metastatic breast cancer.

Directions For Use

Administer intravenously under the supervision of a qualified oncologist. Dosage and infusion rate are determined by the patient's condition and treatment protocol.

Benefits

• Targeted drug delivery to tumors.
• Reduced cardiotoxicity compared to conventional doxorubicin.
• Lower incidence of myelosuppression.
• Improved pharmacokinetic profile.
• Effective against various cancers.
• Enhanced patient tolerability.

Side Effects

• Nausea and vomiting
• Hair loss (alopecia)
• Myelosuppression (low blood counts)
• Stomatitis/mucositis
• Hand-foot syndrome (palmar-plantar erythrodysesthesia)
• Fatigue
• Diarrhea
• Constipation
• Anemia
• Thrombocytopenia
• Neutropenia
• Infusion-related reactions

Safety Measures

• Alcohol - Avoid alcohol during treatment as it can exacerbate liver toxicity and other side effects.
• Pregnancy - Contraindicated during pregnancy due to severe fetal harm risk; effective contraception is essential.
• Breastfeeding - Contraindicated during breastfeeding; discontinue breastfeeding due to potential harm to the infant.
• Liver - Use with extreme caution and dose adjustment in patients with hepatic impairment due to increased toxicity risk.
• Kidney - Use with caution; dose adjustments may be necessary in patients with severe renal impairment.
• Lung - Monitor for pulmonary toxicity, though less common than with conventional doxorubicin; report any respiratory symptoms.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.